@article{1d0d138708604f74ab770df13b0d7ea5,
title = "Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort",
abstract = "Introduction: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults. Methods: Mexican American adults (n = 745), 50 years of age and older, completed annual assessments over a mean of 4 years. Serum collected at baseline was assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl-terminal hydrolase LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14), and chitinase-3-like protein 1 (YKL-40). Results: Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident dementia risk (hazard ratio: 1.611 (95% confidence interval: 1.204-2.155)) and inclusion of additional biomarkers did not improve model fit. Discussion: Among a panel of six blood biomarkers previously associated with neurodegenerative disease, only GFAP predicted incident dementia in our cohort. The findings suggest that blood GFAP levels may aid dementia-risk prediction among Mexican American adults.",
keywords = "Alzheimer's disease, GFAP, Hispanic, Latinos, Mexican American, NFL, UCHL-1, YKL-40, biomarkers, soluble CD14, total tau",
author = "Gonzales, {Mitzi M.} and Wang, {Chen Pin} and Short, {Meghan I.} and Parent, {Danielle M.} and Tiffany Kautz and Daniel MacCarthy and Satizabal, {Claudia L.} and Gonz{\'a}lez, {David Andr{\'e}s} and Royall, {Donald R.} and Habil Zare and Sid O'Bryant and Maestre, {Gladys E.} and Tracy, {Russell P.} and Sudha Seshadri",
note = "Funding Information: The authors would like to thank the Texas Alzheimer's Research and Care Consortium (TARCC) participants, study team, and investigators. This work was made possible by the TARCC funded by the state of Texas through the Texas Council on Alzheimer's Disease and Related Disorders, a TARCC pilot grant [2018-28-81-JI], National Institute on Aging grants [AG054076, AG059421, AG066546] and National Institute of Neurological Disorders and Stroke [NS100605]. In the past 36 months, Dr. Gonzales has received funding from the Texas Alzheimer's Research and Care Consortium, the National Institute on Aging, the Alzheimer's Association, and institutional pilot awards, as well as a travel award from the Alzheimer's Association International Conference. Drs. Short and Satizabal received support from the National Institutes of Health. Dr. Gonzalez has received funding from an institutional pilot award and serves as a member on the American Academy of Clinical Neuropsychology Relevance 2050 Initiative Committee, the Epilepsy Foundation of Central and South Texas Professional Advisory Board, and the National Academy of Neuropsychology Culture & Diversity Committee (all unpaid). Dr. Royall has received funding from the Texas Alzheimer's Research and Care Consortium, an honorarium from the 19th Pacific Rim College of Psychiatrists Scientific Meeting, and has a patent entitled “Serum Biomarker Screen for the Diagnosis of Clinical and Preclinical Alzheimer's Disease” (in Non-Hispanic Whites only) (US 10,634,687). Dr. Zare has received support from the National Institutes of Health and the Texas Alzheimer's Research and Care Consortium. Dr. O'Bryant received funding from the National Institute on Aging and has a sponsored research agreement from Cx Precision Medicine, where he serves as the founding scientist and owns stock. Dr. O'Bryant also reports having multiple patents issued or pending on precision medicine for neurodegenerative diseases. Dr. Maestre has received funding from the National Institute on Aging, the National Eye Institute, and the Texas Alzheimer's Research and Care Consortium. Dr. Maestre serves on the committees for FundaConCiencia Inc and APPREMED. Dr. Tracy has received funding from the National Institutes of Health. Dr. Seshadri has received funding from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and the Alzheimer's Association, as well as consulting fees from Biogen. Dr. Wang, Ms. Parent, Dr. Kautz, and Mr. MacCarthy report no disclosures. Funding Information: The authors would like to thank the Texas Alzheimer's Research and Care Consortium (TARCC) participants, study team, and investigators. This work was made possible by the TARCC funded by the state of Texas through the Texas Council on Alzheimer's Disease and Related Disorders, a TARCC pilot grant [2018‐28‐81‐JI], National Institute on Aging grants [AG054076, AG059421, AG066546] and National Institute of Neurological Disorders and Stroke [NS100605]. In the past 36 months, Dr. Gonzales has received funding from the Texas Alzheimer's Research and Care Consortium, the National Institute on Aging, the Alzheimer's Association, and institutional pilot awards, as well as a travel award from the Alzheimer's Association International Conference. Drs. Short and Satizabal received support from the National Institutes of Health. Dr. Gonzalez has received funding from an institutional pilot award and serves as a member on the American Academy of Clinical Neuropsychology Relevance 2050 Initiative Committee, the Epilepsy Foundation of Central and South Texas Professional Advisory Board, and the National Academy of Neuropsychology Culture & Diversity Committee (all unpaid). Dr. Royall has received funding from the Texas Alzheimer's Research and Care Consortium, an honorarium from the 19th Pacific Rim College of Psychiatrists Scientific Meeting, and has a patent entitled “Serum Biomarker Screen for the Diagnosis of Clinical and Preclinical Alzheimer's Disease” (in Non‐Hispanic Whites only) (US 10,634,687). Dr. Zare has received support from the National Institutes of Health and the Texas Alzheimer's Research and Care Consortium. Dr. O'Bryant received funding from the National Institute on Aging and has a sponsored research agreement from Cx Precision Medicine, where he serves as the founding scientist and owns stock. Dr. O'Bryant also reports having multiple patents issued or pending on precision medicine for neurodegenerative diseases. Dr. Maestre has received funding from the National Institute on Aging, the National Eye Institute, and the Texas Alzheimer's Research and Care Consortium. Dr. Maestre serves on the committees for FundaConCiencia Inc and APPREMED. Dr. Tracy has received funding from the National Institutes of Health. Dr. Seshadri has received funding from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and the Alzheimer's Association, as well as consulting fees from Biogen. Dr. Wang, Ms. Parent, Dr. Kautz, and Mr. MacCarthy report no disclosures. Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.",
year = "2022",
doi = "10.1002/dad2.12298",
language = "English",
volume = "14",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "1",
}